½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 28 March 2025 ¨C 20:00 (CET) ¨C Regulated information 

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, ½ðºÌÓéÀÖ³Ç SA/NV (¡°½ðºÌÓéÀֳǡ± or the ¡°Company) (Euronext Brussels: ½ðºÌÓéÀÖ³Ç) hereby discloses certain information in relation to its Share Repurchase Program 2025. 

Under this program, ½ðºÌÓéÀÖ³Ç has requested a financial intermediary to repurchase up to 700,000 ½ðºÌÓéÀÖ³Ç shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 30 June 2025, effective as from 10 March 2025, to cover current and future obligations under ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2025, ½ðºÌÓéÀÖ³Ç repurchased 201,271 ½ðºÌÓéÀÖ³Ç shares on Euronext Brussels in the period from 21 March 2025 up to and including 27 March 2025, as follows: 

This press release is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

For further information, contact ½ðºÌÓéÀÖ³Ç: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
Antje.Witte@ucb.com

Sahar Yazdian 
T: +32.2.559.9137 
sahar.yazdian@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About ½ðºÌÓéÀÖ³Ç

½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news.